报价延迟最少15分钟:2026/11/04 14:31 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
143.43 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.03/-2.80
|
|
企业价值
9.08B
|
| 资产负债 |
|
每股账面净值
13.01
|
| 现金流量 |
|
现金流量率
0.01
|
| 损益表 |
|
收益
46.02M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations. |
